Navigation Links
BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
Date:7/29/2008

oing surgery. Rocuronium was administered at a standard dose to allow intubation, followed by maintenance doses as required. When 1-2 post-tetanic counts (PTC) were observed following neuromuscular stimulation (deep block), patients were administered either sugammadex or neostigmine plus glycopyrrolate, a current reversal regimen. In the SIGNAL trial, the median time to reversal of muscle relaxation to a train-of-four (TOF) ratio of 0.9 occurred in 2.7 minutes in the sugammadex group compared to 49.0 minutes in the neostigmine/glycopyrrolate group.

The AURORA trial involved adult patients undergoing surgery. Rocuronium was administered at a standard dose to allow intubation, followed by maintenance doses as required. At the reappearance of the second twitch (T2) in a TOF stimulation (moderate block) patients were administered either sugammadex or neostigmine plus glycopyrrolate. In the AURORA trial, the median time to reversal of muscle relaxation to a TOF ratio of 0.9 occurred in 1.4 minutes in the sugammadex group compared to 17.6 minutes in the neostigmine/glycopyrrolate group.

The SPECTRUM trial was conducted in adult patients undergoing surgery to study the immediate reversal of muscle relaxation. Patients were randomized to receive either rocuronium plus sugammadex or the rapid-onset, short- duration muscle relaxant succinylcholine. The trial demonstrated that rocuronium followed by sugammadex is an effective alternative to succinylcholine.

The EC approval of BRIDION follows a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) that was received in May of this year.

About BRIDION (sugammadex)

BRIDION, the first and only selective relaxant binding agent (SRBA), is the first major pharmaceutical advance in the field of anesthesia in two decades. It was specifically designed to rapidly reverse both moderate and deep muscle relaxation induced by the commonly used m
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
2. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
3. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
4. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
7. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
8. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
9. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
10. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
11. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014   DaVita ... ), one of the nation,s largest and most ... DaVita University Academy – the company,s award-winning, leadership ... Nearly 2,000 DaVita teammates from around the globe ... DaVita University Academy is a two-day one-of-a-kind ...
(Date:10/16/2014)... MARLBOROUGH, Mass. , Oct. 16, 2014 ... received CE Mark approval for the ACCOLADE TM ... leads, ACCOLADE pacemakers are the first to enable ... Tesla and 3.0 Tesla systems. In addition, the Boston ... MRI options, allowing higher energy scan sequences, and featuring ...
(Date:10/16/2014)... 2014 The Parenteral Drug Association ... application of single-use, or disposable, systems in ... products with the publication of Technical ... Single-Use Systems in Pharmaceutical Manufacturing. ... systems (SUS) or single-use equipment, has the ...
Breaking Medicine Technology:DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 2DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 3Boston Scientific Announces Pacemaker CE Mark With Options For Magnetic Resonance Imaging 2Boston Scientific Announces Pacemaker CE Mark With Options For Magnetic Resonance Imaging 3Boston Scientific Announces Pacemaker CE Mark With Options For Magnetic Resonance Imaging 4Boston Scientific Announces Pacemaker CE Mark With Options For Magnetic Resonance Imaging 5PDA Offers Help in Applying Single-Use Systems to Bio/Pharma Operations 2
... 18, 2011 The U.S. Food and Drug Administration ... treat patients with acute lymphoblastic leukemia (ALL), who have ... derived asparaginase and pegaspargase chemotherapy drugs used to treat ... Acute lymphoblastic leukemia is a type of ...
... and OXFORD, England, Nov. 18, 2011   EUSA Pharma, a ... supportive care and critical care, today announced that ... approved its orphan drug ERWINAZE™ (asparaginase Erwinia ... leukemia (ALL) in patients with hypersensitivity to ...
Cached Medicine Technology:FDA Approves Erwinaze to Treat a Form of Leukemia 2FDA Approves Erwinaze to Treat a Form of Leukemia 3EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE™ for Treatment of Acute Lymphoblastic Leukemia 2EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE™ for Treatment of Acute Lymphoblastic Leukemia 3EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE™ for Treatment of Acute Lymphoblastic Leukemia 4
(Date:10/19/2014)... Having been working in the garment industry ... customer needs. According to James, one of the company’s top ... or with high-low skirts that add beauty to them. Chiffon ... LunaDress has unveiled its new selection of 2014 long prom ... brand new items are available in over 20 popular designs. ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides many kinds ... designs of 2014 mother of the bride dresses ... offered with big discounts, up to 70% off. All ... enjoy this special offer. , Owing to the ... one of the leading brands in the global market. ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 Visual ... program has just been released to the public ... online body building and fitness community. The commotion ... of DietsAndFitnessGuides.com's Vin Delmonico prompting an investigative review. ... of hitting what is commonly known as a ...
(Date:10/19/2014)... News) -- New stem cell-based research could improve understanding ... a new study suggests. Scientists used stem cells ... a lab dish. They then transplanted the organoids into ... according to the researchers. "This provides a new ... can cause intestinal failure, from genetic disorders appearing at ...
(Date:10/19/2014)... CHICAGO, OCTOBER 20, 2014 – The U.S. Government ... effectively treat Alzheimer,s disease by 2025. However, a ... says the research milestones in the U.S. Government,s ... broadened in scope, increased in scale, and adequately ... A series of proposals by the workgroup to ...
Breaking Medicine News(10 mins):Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6
... on the Indian front has run into rough weather ... Parke-Davis (India). A local court in Hyderabad has ... city. ,The vacation court of the Ranga Reddy ... machinery of Parke-Davis (India) following a petition filed by ...
... has found a new treatment - Vedic vibration technology. ... Vedic Vibration Technology in subjects with arthritis,' revealed that scientists ... in 36 per cent of the patients treated and at ... cent cases. ,The study was recently conducted in Berlin ...
... certain cancers, hepatitis and multiple sclerosis with interferon therapy ... can seriously spoil its quality. Alpha interferon a ... depression. ,A new research now shows that the ... avoid this problem. Almost 50% of people on ...
... Bank, whose website (www.worldbank.org) declares "Our dream is a ... private hospital in Mumbai, India, a move which some ... assistance for projects that will mainly benefit the rich. ... state an International Development Association loan of $134m (89m), ...
... says that women with low risk pregnancies, who live in the ... during pregnancy to 3 - 6 times during pregnancy instead of ... ,However, these women are not more at risk than women ... baby, or have anemia during pregnancy, or spend longer in the ...
... Genetic variations in the HIV strains in Africa make it more ... to researchers. This however does not mean that these drugs will ... to latch on to the protease, which is an enzyme useful ... the drug attaches itself to the protease, then it is easier ...
Cached Medicine News:Health News:The World Bank funds private Hospital in India 2
... are available in 14 configurations including the ... Microgenics Antibody Technology, the SureStep MDMA (Ecstasy) ... immunoassay targeted to detect MDMA that has ... but no cross-reactivity to any isomer of ...
... Tests are available in 14 configurations including ... using Microgenics Antibody Technology, the SureStep™ MDMA ... care immunoassay targeted to detect MDMA that ... MDEA but no cross-reactivity to any isomer ...
AccuSign DOA Series tests include tests for Amphetamines, Barbituates, Benzodiazepines, Cocaine, Methadone, Methamphetamines, Nicotine (Cotinine), Opiates, Phencyclidine, THC, Tricyclic Antidepressan...
... The InstaCheck® multi-drug test device ... and easily. Negative results can ... as 3 minutes; positive results ... simple, one-time urine sample application ...
Medicine Products: